Archived explainer. For the current picture see today's RXRX page.
Why Is RECURSION PHARMACEUT A (RXRX) Stock Up Today?
RECURSION PHARMACEUT A (RXRX) is up +6.99% in the latest session. Our newswire has captured 6 stories on RXRX across 4 sources in the last 36 hours, with AI sentiment reading bullish (avg 61/100).
Recursion Pharmaceuticals (RXRX) shares rose 6.99% to $2.91, driven by a formal agreement with the U.S. Food and Drug Administration regarding the design of a registrational Phase 3 trial. The company aligned with the regulator on the trial structure for REC-4881, a therapy for Familial Adenomatous Polyposis, a rare disease. This regulatory clarity provided a catalyst for the stock after a recent period of decline.
What Happened
Recursion Pharmaceuticals announced that it has reached an agreement with the FDA on the design of a registrational Phase 3 trial for REC-4881. The therapy targets Familial Adenomatous Polyposis, a genetic condition characterized by the growth of polyps in the colon. The alignment allows the company to proceed with the late-stage study as planned.
In related developments, Morgan Stanley lowered its price target for the stock to $5.60 from $5.90. J.P. Morgan maintained a Buy rating on the shares, while Bank of America Merrill Lynch initiated coverage on the company. Recursion also announced its participation in upcoming investor conferences and the signing of Dr. Renata Moon for a publication titled "White Coats, Red Flags."
What The Data Shows
The stock opened at $2.80, representing a 2.9% gap from the prior close of $2.72. The session high reached $2.92 at 9:40 AM ET, while the low was $2.77 at 9:30 AM ET. Trading volume stood at 2.6 million shares, which is 0.1 times the three-month daily average.
Recursion Pharmaceuticals has a market capitalization of $1.8 billion and is currently unprofitable, with a trailing twelve-month EPS of -0.89. Revenue increased by 56.2% over the same period. The stock has a beta of 1.15 and trades within a 52-week range of $2.50 to $5.24. Over the last eight sessions, the stock fell 22.7%, moving from $3.52 to $2.72. The company printed five fresh 52-week highs on November 18, 2026. Recent insider activity includes five sales totaling $701,000 over the last 90 days, with no buys recorded.
What To Watch
Investors will monitor the execution of the Phase 3 trial for REC-4881 as the next major catalyst. The upcoming participation in investor conferences may also provide additional insights into the company's strategic direction.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
RXRX by the numbers
The headlines behind the move
Recursion Pharmaceuticals price target lowered to $5.60 from $5.90 at Morgan Stanley
Recursion aligns with FDA on late-stage trial design for rare disease therapy
Recursion (RXRX) aligns with the FDA regarding a late-stage trial design for its rare disease therapy, REC-4881. Read more here.
Recursion (RXRX) Secures FDA Agreement on Phase 3 Trial Design for REC-4881 in FAP
Recursion Pharmaceuticals aligns with FDA on trial of REC-4881
Recursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous Polyposis
More on RXRX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier RXRX move explainers: 2026-11-18 · 2026-10-16 · 2026-10-15